Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

D. Bertens, S. Vos, P. Kehoe, H. Wolf, F. Nobili, A. Mendonça, I. van Rossum, J. Hort, JL. Molinuevo, M. Heneka, R. Petersen, P. Scheltens, PJ. Visser,

. 2019 ; 11 (1) : 74. [pub] 20190822

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025712

Grant support
115372 Innovative Medicines Initiative - International

INTRODUCTION: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. METHODS: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. RESULTS: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients' wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. CONCLUSIONS: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025712
003      
CZ-PrNML
005      
20201222154044.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13195-019-0525-9 $2 doi
035    __
$a (PubMed)31439020
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Bertens, Daniela $u Alzheimer Centre, Department of Neurology, VU University Medical Centre, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands. d.bertens@vumc.nl.
245    10
$a Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey / $c D. Bertens, S. Vos, P. Kehoe, H. Wolf, F. Nobili, A. Mendonça, I. van Rossum, J. Hort, JL. Molinuevo, M. Heneka, R. Petersen, P. Scheltens, PJ. Visser,
520    9_
$a INTRODUCTION: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. METHODS: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. RESULTS: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients' wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. CONCLUSIONS: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.
650    _2
$a Alzheimerova nemoc $x diagnóza $7 D000544
650    12
$a postoj zdravotnického personálu $7 D001291
650    _2
$a kognitivní dysfunkce $x diagnóza $7 D060825
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neurologie $7 D009462
650    _2
$a prodromální symptomy $7 D062706
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vos, Stephanie $u Alzheimer Centre, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands.
700    1_
$a Kehoe, Patrick $u Learning and Research, Faculty of Health Sciences, University of Bristol, Bristol, UK.
700    1_
$a Wolf, Henrike $u Department of Psychiatry, University of Zurich, Zürich, Switzerland.
700    1_
$a Nobili, Flavio $u Clinical Neurology Unit, Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy.
700    1_
$a Mendonça, Alexandre $u Department of Neurology and Laboratory of Neurosciences, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
700    1_
$a van Rossum, Ineke $u Alzheimer Centre, Department of Neurology, VU University Medical Centre, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
700    1_
$a Hort, Jacub $u Department of Neurology, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Molinuevo, Jose Luis $u BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain. Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain.
700    1_
$a Heneka, Michael $u Clinical Neuroscience, Department of Neurology Clinical Neuroscience Unit, and German Center for Neurodegenerative Disease (DZNE), Bonn, Germany.
700    1_
$a Petersen, Ron $u Mayo Clinic Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging, Rochester, MN, USA.
700    1_
$a Scheltens, Philip $u Alzheimer Centre, Department of Neurology, VU University Medical Centre, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
700    1_
$a Visser, Pieter Jelle $u Alzheimer Centre, Department of Neurology, VU University Medical Centre, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands. pj.visser@vumc.nl. Alzheimer Centre, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands. pj.visser@vumc.nl.
773    0_
$w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 11, č. 1 (2019), s. 74
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31439020 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222154040 $b ABA008
999    __
$a ok $b bmc $g 1599857 $s 1116398
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c 1 $d 74 $e 20190822 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
GRA    __
$a 115372 $p Innovative Medicines Initiative $2 International
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options